Search Results: keywords:"biosimilar drugs"

  • S. 43 — To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.
    Status:Introduced in Senate
    Words:1,131

    S. 43 aims to amend U.S. patent law to create a "safe harbor" that protects companies from patent infringement claims when they submit applications for generic or biosimilar drugs or market them if certain conditions are met. Specifically, the bill ensures that actions like...

    Simple Explanation

    S. 43 is a bill that wants to make it easier for companies to sell cheaper versions of medicine by saying they won't get in trouble for using certain ideas, as long as they don’t copy the special parts of the original medicine.

  • S. 1040 — To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
    Status:Introduced in Senate
    Words:2,835

    S. 1040 is a bill titled the "Drug Competition Enhancement Act" that aims to modify the Federal Trade Commission Act to prohibit a practice known as "product hopping." Product hopping is when a drug manufacturer makes minor changes to a drug to extend its market exclusivity...

    Simple Explanation

    S. 1040 is a rule that tries to stop medicine makers from making tiny changes to their drugs just to keep other companies from making cheaper versions. It lets a special group check if this is happening and make sure everyone plays fair.